Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies

Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Mara Penne, Maryam Sarraf Yazdy, Kruti Sheth Nair, Bruce D. Cheson Tags: Original Study Source Type: research